{"id":"W4388897642","doi":"10.1158/1078-0432.ccr-23-0133","title":"A Phase I/II Study of GSK525762 Combined with Fulvestrant in Patients with Hormone Receptor–positive/HER2-negative Advanced or Metastatic Breast Cancer","year":2023,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":18,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ottawa Hospital; Université Laval; Princess Margaret Cancer Centre","funders":"","keywords":"Dysgeusia; Fulvestrant; Medicine; Metastatic breast cancer; Internal medicine; Breast cancer; Tolerability; Exemestane; Aromatase inhibitor; Oncology; Cancer; Pharmacodynamics; Adverse effect; Estrogen receptor; Pharmacokinetics; Aromatase","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001178027,0.001471672,0.001985532,0.0004715401,0.0003498931,0.0006664279,0.0006909602,0.0009347809,0.003589446],"category_scores_gemma":[0.0007116785,0.0006489136,0.001298067,0.0004324981,0.0009635134,0.0007797765,0.0003014176,0.002346481,0.0008320026],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007103795,"about_ca_system_score_gemma":0.001288354,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008756259,"about_ca_topic_score_gemma":0.001873149,"domain_scores_codex":[0.9996543,0.0001666039,0.00002073676,0.00005872249,0.00003132027,0.00006833347],"domain_scores_gemma":[0.9995753,0.00007167061,0.00008123962,0.00004723496,0.00002741608,0.0001970783],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6575503,0.1304595,0.009733697,0.001307148,0.001794883,0.0004614552,0.0003898273,0.003039324,0.07847419,0.0002692692,0.00291317,0.1136073],"study_design_scores_gemma":[0.4978689,0.4876045,0.008428667,0.00002682381,0.0004321512,0.000215353,0.00005056213,0.000723986,0.003283049,0.0000706689,0.001275018,0.00002027674],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9941496,0.001513153,0.0003860526,0.0002505357,0.00007165234,0.002073716,0.0004798961,0.00006682734,0.001008542],"genre_scores_gemma":[0.9924653,0.001628883,0.001129114,0.0005249329,0.0001155171,0.001690643,0.001118458,0.00001934778,0.001307894],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003589446,"threshold_uncertainty_score":0.01200789,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07633842613163684,"score_gpt":0.4556095102528649,"score_spread":0.3792710841212281,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}